Baidu
map

JCO:结直肠癌原发灶与转移灶的基因表型存在差异

2012-06-25 吴君德 王迈 MedSci原创

  6月4日在线发表于J Clin Oncol的一项比较结直肠癌(CRC)原发灶与转移灶、转移灶之间基因突变情况的研究显示,TP53突变在转移灶中更为常见(53.1%对30.3%),而BRAF突变则在原发肿瘤中更多。   比较基因组杂交(CGH)数据显示,造成原发肿瘤与转移灶突变以及基因拷贝数分布差异的原因,可能是多个不同的CRC原发病灶或治疗相关效应。 原始文献: Va

  6月4日在线发表于J Clin Oncol的一项比较结直肠癌(CRC)原发灶与转移灶、转移灶之间基因突变情况的研究显示,TP53突变在转移灶中更为常见(53.1%对30.3%),而BRAF突变则在原发肿瘤中更多。

  比较基因组杂交(CGH)数据显示,造成原发肿瘤与转移灶突变以及基因拷贝数分布差异的原因,可能是多个不同的CRC原发病灶或治疗相关效应。

原始文献:

Vakiani E, Janakiraman M, Shen R, et al.Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas.J Clin Oncol. 2012 Jun 4.
 
PURPOSE To compare the mutational and copy number profiles of primary and metastatic colorectal carcinomas (CRCs) using both unpaired and paired samples derived from primary and metastatic disease sites. PATIENTS AND METHODSWe performed a multiplatform genomic analysis of 736 fresh frozen CRC tumors from 613 patients. The cohort included 84 patients in whom tumor tissue from both primary and metastatic sites was available and 31 patients with pairs of metastases. Tumors were analyzed for mutations in the KRAS, NRAS, BRAF, PIK3CA, and TP53 genes, with discordant results between paired samples further investigated by analyzing formalin-fixed, paraffin-embedded tissue and/or by 454 sequencing. Copy number aberrations in primary tumors and matched metastases were analyzed by comparative genomic hybridization (CGH).ResultsTP53 mutations were more frequent in metastatic versus primary tumors (53.1% v 30.3%, respectively; P < .001), whereas BRAF mutations were significantly less frequent (1.9% v 7.7%, respectively; P = .01). The mutational status of the matched pairs was highly concordant (> 90% concordance for all five genes). Clonality analysis of array CGH data suggested that multiple CRC primary tumors or treatment-associated effects were likely etiologies for mutational and/or copy number profile differences between primary tumors and metastases. CONCLUSIONFor determining RAS, BRAF, and PIK3CA mutational status, genotyping of the primary CRC is sufficient for most patients. Biopsy of a metastatic site should be considered in patients with a history of multiple primary carcinomas and in the case of TP53 for patients who have undergone interval treatment with radiation or cytotoxic chemotherapies.
 



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1891007, encodeId=4a7e189100ece, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Mon Oct 22 17:13:00 CST 2012, time=2012-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756544, encodeId=5ad51e56544bf, content=<a href='/topic/show?id=880d934525e' target=_blank style='color:#2F92EE;'>#转移灶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93452, encryptionId=880d934525e, topicName=转移灶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb5637174268, createdName=ms6390871039024434, createdTime=Fri Apr 05 21:13:00 CST 2013, time=2013-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452590, encodeId=6959145259029, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 27 13:13:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535096, encodeId=018c153509612, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Wed Jun 27 13:13:00 CST 2012, time=2012-06-27, status=1, ipAttribution=)]
    2012-10-22 lidong40
  2. [GetPortalCommentsPageByObjectIdResponse(id=1891007, encodeId=4a7e189100ece, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Mon Oct 22 17:13:00 CST 2012, time=2012-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756544, encodeId=5ad51e56544bf, content=<a href='/topic/show?id=880d934525e' target=_blank style='color:#2F92EE;'>#转移灶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93452, encryptionId=880d934525e, topicName=转移灶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb5637174268, createdName=ms6390871039024434, createdTime=Fri Apr 05 21:13:00 CST 2013, time=2013-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452590, encodeId=6959145259029, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 27 13:13:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535096, encodeId=018c153509612, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Wed Jun 27 13:13:00 CST 2012, time=2012-06-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1891007, encodeId=4a7e189100ece, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Mon Oct 22 17:13:00 CST 2012, time=2012-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756544, encodeId=5ad51e56544bf, content=<a href='/topic/show?id=880d934525e' target=_blank style='color:#2F92EE;'>#转移灶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93452, encryptionId=880d934525e, topicName=转移灶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb5637174268, createdName=ms6390871039024434, createdTime=Fri Apr 05 21:13:00 CST 2013, time=2013-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452590, encodeId=6959145259029, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 27 13:13:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535096, encodeId=018c153509612, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Wed Jun 27 13:13:00 CST 2012, time=2012-06-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1891007, encodeId=4a7e189100ece, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Mon Oct 22 17:13:00 CST 2012, time=2012-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756544, encodeId=5ad51e56544bf, content=<a href='/topic/show?id=880d934525e' target=_blank style='color:#2F92EE;'>#转移灶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93452, encryptionId=880d934525e, topicName=转移灶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb5637174268, createdName=ms6390871039024434, createdTime=Fri Apr 05 21:13:00 CST 2013, time=2013-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452590, encodeId=6959145259029, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 27 13:13:00 CST 2012, time=2012-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535096, encodeId=018c153509612, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Wed Jun 27 13:13:00 CST 2012, time=2012-06-27, status=1, ipAttribution=)]
    2012-06-27 tastas

相关资讯

我国应重视结直肠癌的筛查

来源:中国医学论坛报   CRC是消化系统常见的恶性肿瘤,目前发病率位居第4位。如何预防CRC的发生成为人们关注的焦点。   西方国家很早就开始重视CRC的研究,早在1998年,有学者就明确提出CRC腺瘤—不典型增生—癌的癌变模式。基于这一机制,美国最早提出CRC的筛查方案,并将其纳入医疗保障体系之中,在全国大力推广。   最近公布的美国CDC数据可明显看出这一筛查方案的效果,年发病率3.4

Baidu
map
Baidu
map
Baidu
map